Callan Family Office LLC Makes New Investment in Charles River Laboratories International, Inc. $CRL

Callan Family Office LLC purchased a new position in Charles River Laboratories International, Inc. (NYSE:CRL) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 2,243 shares of the medical research company’s stock, valued at approximately $340,000.

Several other institutional investors and hedge funds have also bought and sold shares of CRL. Brooklyn Investment Group grew its holdings in Charles River Laboratories International by 93.5% in the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock worth $27,000 after purchasing an additional 86 shares during the last quarter. Cromwell Holdings LLC grew its holdings in Charles River Laboratories International by 542.9% in the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock worth $27,000 after purchasing an additional 152 shares during the last quarter. HM Payson & Co. purchased a new position in Charles River Laboratories International in the first quarter worth $31,000. Family Legacy Financial Solutions LLC purchased a new position in Charles River Laboratories International in the second quarter worth $71,000. Finally, ORG Wealth Partners LLC grew its holdings in Charles River Laboratories International by 49.8% in the second quarter. ORG Wealth Partners LLC now owns 496 shares of the medical research company’s stock worth $77,000 after purchasing an additional 165 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 800 shares of the firm’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the sale, the executive vice president directly owned 24,116 shares in the company, valued at $3,800,681.60. This trade represents a 3.21% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Trading Up 0.5%

Shares of Charles River Laboratories International stock opened at $170.94 on Thursday. The firm has a 50-day simple moving average of $159.76 and a two-hundred day simple moving average of $147.90. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $230.02. The company has a market cap of $8.41 billion, a P/E ratio of -128.53, a price-to-earnings-growth ratio of 4.55 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, beating analysts’ consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The firm had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $983.76 million. During the same period last year, the firm earned $2.80 EPS. The company’s quarterly revenue was up .6% on a year-over-year basis. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Evercore ISI lifted their price target on shares of Charles River Laboratories International from $190.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, October 3rd. Jefferies Financial Group upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $142.00 to $195.00 in a research note on Tuesday, September 9th. Barclays upgraded shares of Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $165.00 to $195.00 in a research note on Thursday, October 2nd. Citigroup upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $150.00 to $200.00 in a research note on Wednesday, July 9th. Finally, Wall Street Zen upgraded shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. Eight research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $179.93.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).